Medicago, based in Quebec, Canada, will open a vaccine production facility in Durham, North Carolina's Research Triangle Park. The company will create 85 jobs as part of the project, which is partly funded by a $128,000 grant from the One North Carolina Fund.
"North Carolina's quality of work force, its training programs, and overall understanding of biotech development models were critical factors in our decision to locate in RTP," said Andy Sheldon, president and CEO of Medicago. "We are thrilled with our decision to build our vaccine facility in one of the largest and successful technology parks."
Medicago has received a $21 million research grant from the Defense Advanced Research Projects Agency (DARPA) to improve the production process of H1N1 vaccines. The company's project represents a total investment of more than $32 million in Research Triangle Park.